The OncLive Immunotherapy in Lung Cancer condition center page is a comprehensive resource for clinical news and expert insights on available and investigational immunotherapies in lung cancer. This page features news articles, interviews in written and video format, and podcasts that focus on updates with checkpoint inhibitors and the ongoing research with this type of treatment in non–small cell lung cancer and small cell lung cancer.
March 25th 2024
Durvalumab/chemoradiation did not significantly improve survival vs chemoradiation alone in patients with unresectable non–small cell lung cancer.
Immunotherapy Takes Hold in Frontline Advanced Nonsquamous NSCLC
November 18th 2019Jyoti D. Patel, MD, FASCO, discusses the implications of genetic testing, the lasting impact of the KEYNOTE and IMpower trials in patients with advanced nonsquamous non–small cell lung cancer, and considerations for treatment selection.
Durvalumab Regimens Improve PFS in Frontline Metastatic NSCLC
October 29th 2019The addition of durvalumab (Imfinzi) to platinum-based chemotherapy demonstrated a statistically significant and clinically meaningful improvement in progression-free survival compared with chemotherapy alone in patients with previously untreated metastatic non–small cell lung cancer.
Nivolumab/Ipilimumab Plus Chemo Improves OS in Frontline NSCLC
October 22nd 2019The first-line combination of nivolumab (Opdivo) plus low-dose ipilimumab (Yervoy) given concomitantly with 2 cycles of chemotherapy showed superior overall survival compared with up to 4 cycles of chemotherapy alone followed by optional maintenance treatment in patients with advanced non–small cell lung cancer.
Dr. Borghaei on the Clinical Utility of PD-L1 in Advanced NSCLC
October 17th 2019Hossein Borghaei, DO, MS, chief, Division of Thoracic Medical Oncology, director, Lung Cancer Risk Assessment, professor, Department of Hematology/Oncology, co-director, Immune Monitoring Facility, Lung Cancer and Mesothelioma TRDG member, and Gloria and Edmund M. Dunn Chair in Thoracic Oncology, Fox Chase Cancer Center, discusses the clinical utility of PD-L1 in advanced non–small cell lung cancer (NSCLC).
Dr. Borghaei on Anticipated Trials Evaluating Immunotherapy in NSCLC
October 5th 2019Hossein Borghaei, DO, MS, chief, Division of Thoracic Medical Oncology, director, Lung Cancer Risk Assessment, associate professor, Department of Hematology/Oncology, Fox Chase Cancer Center, discusses necessary research and anticipated trials evaluating immunotherapy in advanced non–small cell lung cancer (NSCLC).
Durvalumab Combo Improves QoL, Reduces New Lesions in Small Cell Lung Cancer
Durvalumab added to etoposide and platinum-based chemotherapy as a first-line treatment for patients with extensive-stage small cell lung cancer delays development of new lesions and improves patient-reported outcomes compared with etoposide and platinum-based therapy alone.
Practice-Changing PACIFIC Trial Opens Road for Immunotherapy in Stage III NSCLC
October 1st 2019Edgardo S. Santos, MD, FACP, FCCP, discusses data from the PACIFIC trial and how it has changed the standard of care for stage III non–small cell lung cancer patients whose disease has not progressed following concurrent platinum-based chemoradiation.
Frontline Nivolumab/Ipilimumab Combo Improves OS in Advanced NSCLC
September 28th 2019The first-line combination of nivolumab and ipilimumab led to a clinically meaningful improvement in overall survival versus chemotherapy in patients with advanced non–small cell lung cancer, regardless of PD-L1 expression.